Mega Act-D Tablet is a combination pharmaceutical formulation containing Trypsin (48 mg), Bromelain (90 mg), Rutoside (100 mg), and Diclofenac (50 mg), designed to provide effective anti-inflammatory, analgesic, and fibrinolytic effects. Trypsin and Bromelain are proteolytic enzymes that facilitate the breakdown of proteins, promoting the reduction of edema and inflammation by enhancing the absorption of inflammatory exudates. Rutoside, a bioflavonoid, acts as a vascular protective agent by strengthening capillary walls and reducing capillary permeability, thereby minimizing bruising and swelling. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes (COX-1 and COX-2), leading to decreased synthesis of prostaglandins responsible for pain, inflammation, and fever. This synergistic combination is indicated for the management of acute musculoskeletal conditions such as sprains, strains, contusions, postoperative inflammation, and other soft tissue injuries. Mega Act-D Tablet provides rapid relief from pain and inflammation while promoting faster recovery through enhanced tissue repair mechanisms. It should be used under medical supervision, with caution advised in patients with gastrointestinal, renal, or hepatic impairments, and contraindicated in individuals with known hypersensitivity to any component. Adherence to prescribed dosage and monitoring for adverse effects is essential to ensure therapeutic efficacy and safety.